Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.

Bibliographic Details
Title: Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Authors: Muranushi H; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kobayashi M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Hematology, Japan Baptist Hospital, Kyoto, Japan., Maeda T; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan., Kitano T; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan., Tsuji M; Department of Hematology and Immunology, Otsu Red Cross Hospital, Otsu, Japan., Ueda Y; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan., Ishikawa T; Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan., Nohgawa M; Department of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan., Watanabe M; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan., Imada K; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan., Moriguchi T; Department of Internal Medicine, Kyoto-Katsura Hospital, Kyoto, Japan., Itoh M; Department of Hematology, Kyoto City Hospital, Kyoto, Japan., Ohno H; Department of Hematology, Tenri Hospital, Tenri, Japan., Yonezawa A; Department of Hematology, Kokura Memorial Hospital, Kitakyushu, Japan., Hirata H; Department of Hematology, Kansai Electric Power Hospital, Osaka, Japan., Arima N; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan., Asagoe K; Department of Hematology and Oncology, Shiga General Hospital, Moriyama, Japan., Anzai N; Department of Hematology and Oncology, Takatsuki Red Cross Hospital, Takatsuki, Japan., Nagata K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Yasuno S; Clinical Research Support Center, The Jikei University School of Medicine, Tokyo, Japan., Kuwabara Y; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan., Kitao H; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan., Kim I; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan., Kawagishi K; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan., Ueshima K; Center for Accessing Early Promising Treatment, Kyoto University Hospital, Kyoto, Japan., Tominari S; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan., Nakayama T; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan., Yamashita K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Source: Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 239-248.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE
Database: MEDLINE Complete
Full text is not displayed to guests.
Description
ISSN:1607-8454
DOI:10.1080/16078454.2022.2032915